Form 8-K - Current report:
SEC Accession No. 0001279569-23-000607
Filing Date
2023-05-09
Accepted
2023-05-09 09:01:10
Documents
13
Period of Report
2023-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K COVER PAGE essapharma8k.htm   iXBRL 8-K 25690
2 NEWS RELEASE DATED MAY 9, 2023 ex991.htm EX-99.1 56973
  Complete submission text file 0001279569-23-000607.txt   266909

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA epix-20230509.xsd EX-101.SCH 2965
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE epix-20230509_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE epix-20230509_pre.xml EX-101.PRE 22363
7 EXTRACTED XBRL INSTANCE DOCUMENT essapharma8k_htm.xml XML 3704
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37410 | Film No.: 23900202
SIC: 2834 Pharmaceutical Preparations